Biophytis Shares Drop 11% After Request for Meeting With FDA on Covid-19 Treatment
By Chris Wack
Biophytis shares fell 11% to $2.40 after the company said it has filed for a pre-submission meeting request with the Food and Drug Administration to discuss filing for emergency use authorization in the U.S. for Sarconeos in the treatment of Covid-19.
The stock dropped 13% on Wednesday after the company priced a registered direct offering valued at $3.8 million. The stock is down 74% in the past 12 months.
The biotechnology company said this request is a further key step in defining the conditions for rapid market access in the U.S. for Sarconeos, following a similar process initiated with the European Medicine Agency in May.
Biophytis said that depending on feedback from the FDA, it could consider filing an emergency use application by the end of 2023 or in the first half of 2024.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 20, 2023 13:06 ET (17:06 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett
-
Cognizant Earnings: Improved Profitability Buttresses Results as Customer Spending Remains Muted
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths